Metabolic Research

UBT251

InvestigationalWeight & metabolic
Not yet scored

BioHarmony verdict

Awaiting review

No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.

What is UBT251?

Novo Nordisk reports that a Phase 1a/2b trial has started for UBT251, an investigational triple agonist. It remains early-stage and has not been established as safe or effective for routine use.

Dosing as published

No approved-label or study protocol is recorded for UBT251 yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalInvestigational
CompoundingEligibility not established.
Last checked2026-07-13
Next review2026-10-11

Primary sources

  1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
  2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
  3. 6.1/10TirzepatideWorth tryingWeight & metabolicFDA-approved product existsTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
  4. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.